Welcome to our dedicated page for Caredx news (Ticker: CDNA), a resource for investors and traders seeking the latest updates and insights on Caredx stock.
CareDx, Inc. reports developments in precision medicine for transplant patients and caregivers. The company’s updates center on non-invasive molecular testing for heart, kidney, and lung transplantation, including AlloSure, AlloMap, HeartCare, and related evidence generation for post-transplant surveillance, risk assessment, and longitudinal patient management.
CareDx news also covers operating and financial results for testing services and patient and digital solutions, product and platform launches such as VANTx clinical data analytics, clinical conference presentations, material agreements, and Nasdaq-related governance matters including inducement equity awards.
CareDx (Nasdaq: CDNA) awarded inducement restricted stock unit grants to 35 new employees totaling 82,137 RSUs on February 24, 2026, under its 2016 and 2025 Inducement Equity Incentive Plans in accordance with Nasdaq Listing Rule 5635(c)(4).
The RSUs vest over four years: 25% on the first anniversary of each employee's vesting commencement date and then 1/16th quarterly thereafter, subject to continued service.
CareDx (Nasdaq: CDNA) announced that Keith Kennedy, currently Chief Operating Officer, will also assume the role of Chief Financial Officer effective February 26, 2026.
Kennedy brings over 20 years of healthcare leadership, seven years of public-company CFO experience, prior CFO roles including PharmaLogic (Apr 2022–Sep 2024), and credentialing as a CFA and CPA. Nathan Smith will step down as CFO, as announced on the company’s quarterly earnings call.
Summary not available.
CareDx (Nasdaq: CDNA) will participate in the Raymond James 47th Annual Institutional Investors Conference in Orlando, FL on Tuesday, March 3, 2026.
The company is expected to present its recent developments in transplant precision medicine and engage with investors and analysts during the conference.
CareDx (Nasdaq: CDNA) announced clinical validation of AlloHeme, an AI‑powered, NGS blood test to surveil relapse in AML and MDS after allogeneic HCT.
The ACROBAT study (198 subjects, 40 relapse events) showed 85% sensitivity, 92% specificity, 95% NPV, 79% PPV, AUC 0.89, and a median 41‑day lead time. CareDx expects CLIA readiness in 2026, commercial launch in 2027, and payer coverage in 2028.
CareDx (Nasdaq: CDNA) will report fourth quarter and full year 2025 financial results after market close on Tuesday, February 24, 2026. A webcast and conference call will be held at 1:30 p.m. PT / 4:30 p.m. ET.
Live and archived webcast access is available on the Events & Presentations section of CareDx's Investor Relations website, and telephone participation requires registration to receive a dial-in number and unique PIN.
CareDx (Nasdaq: CDNA) will present pivotal clinical validation data from the ACROBAT study of AlloHeme at the 2026 Tandem Meetings (Feb 4-7) and will host an investor webcast Feb 12. The ACROBAT trial is a prospective, blinded, multi-center study (11 U.S. centers) reporting complete 24-month follow-up for relapse surveillance after allogeneic HCT in AML and MDS.
The oral presentation includes 24-month results; the webcast will review clinical validation data and the commercial launch timeline for AlloHeme.
CareDx (Nasdaq: CDNA) will participate in the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference in Snowbird, UT on Tuesday, February 10, 2026. The company is described as focused on precision medicine and on discovery, development, and commercialization of clinically differentiated, high‑value healthcare solutions for transplant patients and caregivers.
CareDx (Nasdaq: CDNA) reported preliminary, unaudited results for Q4 and full year 2025. Q4 revenue ~ $108M (+25% YoY) with testing services revenue ~ $78M (+23% YoY) and testing volume ~ 53,000 (+17% YoY). FY2025 revenue ~ $380M (+14% YoY) with testing services ~ $274M (+10% YoY), testing volume ~ 200,000 (+14% YoY), patient & digital solutions ~ $57M (+31% YoY) and product revenue ~ $48M (+19% YoY).
Average revenue per test ~ $1,470 (includes ~ $5M prior period revenue). cash, cash equivalents and marketable securities ~ $200M at 12/31/2025. Share repurchases: $12M in Q4 (773,000 shares) and $88M for year (5.8M shares) at average prices shown. Results are preliminary and may change after audit.
CareDx (Nasdaq: CDNA) and 10x Genomics (Nasdaq: TXG) launched ImmuneScape, a multiomics research program to map immune biology in transplant rejection and therapeutic response.
The collaboration will use 10x Xenium spatial and Chromium Flex single cell platforms to profile FFPE biopsy samples at cellular resolution, focusing on antibody-mediated rejection (AMR) and microvascular inflammation (MVI). Insights are intended to support future diagnostic development and to correlate tissue-level immune architecture with clinical outcomes, including response to anti-CD38 therapies.